Analyst Price Targets — AMRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 15, 2026 11:59 am | Ashwani Verma | UBS | $23.00 | $17.10 | TheFly | Amneal Pharmaceuticals price target raised to $23 from $19 at UBS |
| May 20, 2026 9:13 am | Glen Santangelo | Barclays | $16.00 | $11.81 | TheFly | Amneal Pharmaceuticals price target raised to $16 from $15 at Barclays |
| April 17, 2026 8:56 am | Ashwani Verma | UBS | $19.00 | $13.09 | TheFly | Amneal Pharmaceuticals initiated with a Buy at UBS |
| March 2, 2026 12:16 pm | Les Sulewski | Truist Financial | $17.00 | $13.45 | StreetInsider | Amneal Pharmaceuticals (AMRX) PT Raised to $17; Truist: 'Stock pullback a great entry point' |
| January 7, 2026 12:20 pm | — | Truist Financial | $15.00 | $12.99 | TheFly | Amneal Pharmaceuticals price target raised to $15 from $14 at Truist |
| December 8, 2025 9:24 pm | — | Barclays | $15.00 | $11.87 | TheFly | Amneal Pharmaceuticals initiated with an Overweight at Barclays |
| March 3, 2025 11:25 am | — | Barclays | $11.00 | $8.76 | TheFly | Amneal Pharmaceuticals price target raised to $11 from $10 at Barclays |
| November 11, 2024 12:22 pm | David Amsellem | Piper Sandler | $11.00 | $8.29 | StreetInsider | Amneal Pharmaceuticals (AMRX) PT Raised to $11 at Piper Sandler |
| October 2, 2024 8:53 am | Les Sulewski | Truist Financial | $12.00 | $8.70 | TheFly | Amneal Pharmaceuticals price target raised to $12 from $10 at Truist |
| October 1, 2024 1:42 pm | Les Sulewski | Truist Financial | $10.00 | $8.70 | StreetInsider | Truist Securities Reiterates Buy Rating on Amneal Pharmaceuticals (AMRX) |
Latest News for AMRX
BRIDGEWATER, N.J., July 17, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), today announced that it has received U.S. Food and Drug Administration (FDA) approval for additional strengths and vial presentations of iohexol injection, 350 mg iodine/mL in 50 mL, 75 mL and 100 mL vials, as well as 300 mg iodine/mL in 50 mL vial. Amneal plans to launch these products in…
BRIDGEWATER, N.J., July 09, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced it will report second quarter 2026 financial results on Thursday, July 30, 2026, before market open. The Company will host an audio webcast at 8:30 a.m. ET.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
MILAN and BRIDGEWATER, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Zambon and Amneal Pharmaceuticals today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson's disease and…
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AMRX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.